Effect of 1 alpha-vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment.
The effects of 1 alpha-vitamin D3 were studied for 6 months in 2-month-old male and female rats on a moderately low calcium diet with or without low-dose prednisolone treatment. Both cortical bone mechanical and biochemical properties were examined. Femoral bone specimens were subjected to torsional loading tests. With age, bone strength and stiffness increased in both sexes, accompanied by an increased degree of mineralization (bone ash and calcium concentrations). During growth, strength and stiffness increased more in male than in female rats. When 1 alpha-vitamin D3 (0.5 micrograms/kg/day) was given alone, bone mechanical competence improved significantly whereas insulin-like growth factor-I (IGF-I) and calcium concentrations in the bone matrix were significantly reduced. Treatment with low-dose prednisolone (0.5 mg/kg/day) alone did not influence bone mechanical properties compared with intact control rats (without prednisolone) although a significant reduction in calcium concentration and an increased phosphorus concentration were measured. A combined therapy with prednisolone and 1 alpha-vitamin D3 significantly increased bone strength, toughness, and stiffness compared with control bones. Both mineralization degree (ash and calcium concentration) and IGF-I concentration were  decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
Aerssens
J
J
Arthritis and Metabolic Bone Disease Research Unit, K. U. Leuven, Belgium.
Van Audekercke
R
R
Talalaj
M
M
Van Vlasselaer
P
P
Bramm
E
E
Geusens
P
P
Dequeker
J
J
D000818:Animals; D001696:Biomechanical Phenomena; D001835:Body Weight / Q000502:physiology; D015519:Bone Density / Q000187:drug effects; D001857:Bone Matrix / Q000187:drug effects* / Q000378:metabolism; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002136:Calcium, Dietary / Q000008:administration & dosage; D002762:Cholecalciferol / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005269:Femur / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D015675:Osteocalcin / Q000378:metabolism; D010758:Phosphorus / Q000378:metabolism; D011239:Prednisolone / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012727:Sex Characteristics; D016212:Transforming Growth Factor beta / Q000378:metabolism; D016474:Weight-Bearing
D002136:Calcium, Dietary; D016212:Transforming Growth Factor beta; D015675:Osteocalcin; D002762:Cholecalciferol; D010758:Phosphorus; D007334:Insulin-Like Growth Factor I; D011239:Prednisolone; D002118:Calcium